Welcome to our dedicated page for Citius Pharmaceuticals SEC filings (Ticker: CTXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Citius Pharmaceuticals (CTXR) means sifting through pages of trial protocols, FDA correspondence and financing notes. Those details hide inside dense 10-Ks, sudden 8-K material events and rapid-fire Form 4 insider trades鈥攅xactly where pivotal data on LYMPHIR, Mino-Lok and Halo-Lido first surface.
Stock Titan鈥檚 AI solves that problem. Our engine reads every Citius Pharmaceuticals quarterly earnings report 10-Q filing, flags shifts in R&D burn, and translates footnotes into plain English. AG真人官方-time alerts push Citius Pharmaceuticals Form 4 insider transactions the moment executives buy or sell, while concise summaries turn a 300-page Citius Pharmaceuticals annual report 10-K simplified into a five-minute brief. If you鈥檙e wondering how to interpret an 8-K describing Phase 3 results, our platform highlights trial endpoints and potential impact on approvals.
Here鈥檚 what investors routinely search for鈥攁nd instantly find in one place:
- Citius Pharmaceuticals insider trading Form 4 transactions with contextual AI commentary.
- Citius Pharmaceuticals proxy statement executive compensation showing incentive alignment before data catalysts.
- Citius Pharmaceuticals 8-K material events explained鈥攆rom FDA meeting minutes to merger updates.
- Citius Pharmaceuticals earnings report filing analysis that links cash runway to trial timelines.
- Guidance on understanding Citius Pharmaceuticals SEC documents with AI for faster due diligence.
Every filing鈥�10-K, 10-Q, 8-K, S-3, or definitive proxy鈥攍ands on this page seconds after EDGAR posts, then is decoded by expert-trained AI. Save hours, spot catalyst-moving disclosures early, and follow Citius Pharmaceuticals executive stock transactions Form 4 in real time鈥攁ll without plowing through biotech jargon.
Myron Z. Holubiak, Vice Chairman and a director of Citius Pharmaceuticals (CTXR), reported the disposition of 79,690 shares of common stock and amendments to two outstanding warrants on 08/08/2025. The warrant amendments cancelled the prior warrants and granted replacement warrants exercisable into 31,373 and 22,344 shares, each extended by one year.
The filing lists multiple stock options and warrants remaining beneficially owned by the reporting person, including direct options exercisable into a total of 107,667 common shares and warrants covering 53,717 common shares. Certain options are held indirectly by the reporting person鈥檚 daughter and are disclaimed. All share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024.
Citius Pharmaceuticals reported that it has issued a press release announcing its results of operations for the third quarter of fiscal 2025. The company states the press release is furnished as Exhibit 99.1 to the Form 8-K and is incorporated by reference into the report. The filing explains that the information in Item 2.02, including Exhibit 99.1, is furnished rather than filed for purposes of the Exchange Act and therefore is not subject to the same liabilities as a filed disclosure.
The Form 8-K lists the furnished exhibit and an interactive cover page document, and it is signed on behalf of the registrant by the chairman and chief executive officer. No financial line items, operating metrics, or forward-looking guidance appear within the 8-K text itself; readers must refer to Exhibit 99.1 for the underlying results.
Citius Pharmaceuticals reported no revenues for the periods presented while preparing for the commercial launch of LYMPHIR, an FDA-approved immunotherapy the company expects to launch in the fourth quarter of 2025. The company had $6.09 million in cash and cash equivalents and $17.21 million of inventory (finished goods and work鈥慽n鈥憄rocess) at June 30, 2025, and total assets of $127.68 million. For the nine months ended June 30, 2025 the company recorded a net loss of $30.99 million and used $14.67 million of cash in operating activities. Net loss per share for the nine months was $3.27 on a weighted average of 9.02 million shares.
Liquidity remains a material issue: working capital was negative roughly $27.2 million at June 30, 2025 and management states available cash is expected to fund operations only through September 2025, creating substantial doubt about the company鈥檚 ability to continue as a going concern. Significant near鈥憈erm obligations include a $28.4 million license payable and an outstanding Milestone balance to Dr. Reddy鈥檚 of $22.5 million (partially deferred by agreement). The company raised net financing proceeds of approximately $16.5 million during the period, entered distribution arrangements to support LYMPHIR commercialization, and subsequently regained Nasdaq compliance.
FAQ
What is the current stock price of Citius Pharmaceuticals (CTXR)?
What is the market cap of Citius Pharmaceuticals (CTXR)?
